Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Ikena Oncology Inc (IKNA)

Ikena Oncology Inc (IKNA)
1.0500 x 10 1.4500 x 10
Post-market by (Cboe BZX)
1.1100 -0.0300 (-2.63%) 04/16/25 [NASDAQ]
1.0500 x 10 1.4500 x 10
Post-market 1.1100 unch (unch) 16:00 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0600
Day High
1.1810
Open 1.1200
Previous Close 1.1400 1.1400
Volume 51,700 51,700
Avg Vol 81,415 81,415
Stochastic %K 44.69% 44.69%
Weighted Alpha -35.45 -35.45
5-Day Change +0.0100 (+0.91%) +0.0100 (+0.91%)
52-Week Range 0.9707 - 1.9400 0.9707 - 1.9400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,014
  • Shares Outstanding, K 48,258
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,230 K
  • EBIT $ -59 M
  • EBITDA $ -60 M
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.25
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9707 +14.35%
on 04/09/25
Period Open: 1.3400
1.4300 -22.38%
on 03/24/25
-0.2300 (-17.16%)
since 03/14/25
3-Month
0.9707 +14.35%
on 04/09/25
Period Open: 1.5100
1.6000 -30.63%
on 02/13/25
-0.4000 (-26.49%)
since 01/16/25
52-Week
0.9707 +14.35%
on 04/09/25
Period Open: 1.2700
1.9400 -42.78%
on 12/23/24
-0.1600 (-12.60%)
since 04/16/24

Most Recent Stories

More News
Traws Pharma Announces Management Updates

TRAW : 1.99 (-6.57%)
IOVA : 3.07 (-4.95%)
IKNA : 1.1100 (-2.63%)
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

IKNA : 1.1100 (-2.63%)
Ikena Oncology Reports Third Quarter 2024 Financial Results

IKNA : 1.1100 (-2.63%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of...

IKNA : 1.1100 (-2.63%)
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Advancement across Company’s pipeline towards regulatory and data milestones...

IKNA : 1.1100 (-2.63%)
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 1.1100 (-2.63%)
Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 1.1100 (-2.63%)
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary...

IKNA : 1.1100 (-2.63%)
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier...

IKNA : 1.1100 (-2.63%)
Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration

Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena’s and VHIO’s leadership in research, translational science, and...

IKNA : 1.1100 (-2.63%)

Business Summary

Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States....

See More

Key Turning Points

3rd Resistance Point 1.2950
2nd Resistance Point 1.2380
1st Resistance Point 1.1740
Last Price 1.1100
1st Support Level 1.0530
2nd Support Level 0.9960
3rd Support Level 0.9320

See More

52-Week High 1.9400
Fibonacci 61.8% 1.5697
Fibonacci 50% 1.4554
Fibonacci 38.2% 1.3410
Last Price 1.1100
52-Week Low 0.9707

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro